KURT SCHMECKPEPER: Open Payments
NPI 1346425287 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,291 in 113 payments from 37 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $2,291
Food & beverage: $1,963Education: $329
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 7 | $241 |
| Janssen Biotech, Inc. | 10 | $183 |
| Daiichi Sankyo Inc. | 5 | $165 |
| Celgene Corporation | 14 | $161 |
| Novartis Pharmaceuticals Corporation | 10 | $152 |
| ABBVIE INC. | 7 | $140 |
| Merck Sharp & Dohme LLC | 6 | $112 |
| SEAGEN INC. | 1 | $100 |
| AstraZeneca Pharmaceuticals LP | 4 | $92 |
| TerSera Therapeutics LLC | 3 | $79 |
Products named: Vyloy, Enhertu, REBLOZYL, VENCLEXTA, KEYTRUDA, RYBREVANT, BRUKINSA, PLUVICTO.
Industry payments across NE — which companies pay providers there.
